Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TrkC

TrkC

Brief Information

Name:Neurotrophic tyrosine kinase receptor type 3
Target Synonym:Trk-C,NTRK3,NT-3 growth factor receptor,TrkC tyrosine kinase,Neurotrophic Receptor Tyrosine Kinase 3,Neurotrophic Tyrosine Kinase, Receptor, Type 3,GP145-TrkC,TRKC,ETS Related Protein-Neurotrophic Receptor Tyrosine Kinase Fusion Protein,Tyrosine Kinase Receptor C,ETV6-NTRK3 Fusion,Gp145(TrkC),Receptor, trkC,EC 2.7.10,EC:2.7.10.1,Neurotrophic Tyrosine Kinase Receptor Type 3,EC 2.7.10.1
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TRC-H5256 Human Human TrkC / NTRK3 Protein, Fc Tag (MALS verified)
TRC-H5256-structure
TRC-H5256-sds
ACRO Quality

Part of Bioactivity data

TRC-H5256-MALS-HPLC
TrkC MALS images

The purity of Human TrkC Protein, Fc Tag (Cat. No. TRC-H5256) is more than 90% and the molecular weight of this protein is around 185-215 kDa verified by SEC-MALS.

TRC-H5256-ELISA
 TrkC ELISA

Immobilized Human NT-3 / Neurotrophin-3 Protein at 2 μg/mL (100 μL/well) can bind Human TrkC Protein, Fc Tag (Cat. No. TRC-H5256) with a linear range of 0.3-5 ng/mL (QC tested).

Synonym Name

NTRK3,TRKC,gp145

Background

TrkC tyrosine kinase is also known as Trk-C receptor, NT-3 growth factor receptor and neurotrophic tyrosine kinase receptor type 3, is a member of the NTRK family which mediates the biological activities of neurotrophins. The primary location of TrkC expression is in the nervous system and, specifically, in regions of the CNS. Low level TrkC expression has also been observed in a wide variety of tissues outside the nervous system. TrkC is part of the large family of receptor tyrosine kinases which includes TrkA and TrkB. Also, there are other neurotrophic factors structurally related to NT-3: NGF, BDNF and NT-4. While TrkB mediates the effects of BDNF, NT-4 and NT-3, TrkA is bound and thereby activated only by NGF. Further, TrkC binds and is activated only by NT-3. TrkB binds BDNF and NT-4 more strongly than it binds NT-3. TrkC binds NT-3 more strongly than TrkB does. Upon neurotrophin binding, TrkC phosphorylates itself and down stream molecules of the related pathways, and therefore mediates the NT3-stimulated neurotrophic effects. This protein thus leads to cell proliferation, differentiation and plays a role in the development of proprioceptive neurons.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Entrectinib NMS-E628; RXDX-101; RG-6268 Approved Nerviano Medical Sciences Srl 罗圣全, Rozlytrek Japan Carcinoma, Non-Small-Cell Lung Chugai Pharmaceutical Co Ltd 2019-06-18 Sarcoma; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Acute; Glioma; Hepatic Insufficiency; Colorectal Neoplasms; Lymphoproliferative Disorders; Breast Neoplasms; Cholangiocarcinoma; Solid tumours; Brain Neoplasms; Neuroendocrine Tumors; Central Nervous System Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Neoplasms; Carcinoma, Renal Cell; Head and Neck Neoplasms; Ovarian Neoplasms; Skin Melanoma; Hematologic Neoplasms Details
Larotrectinib sulfate LOXO-101; ARRY-470; BAY-2757556 Approved Array Biopharma Vitrakvi, 维泰凯 United States Solid tumours Bayer Healthcare Pharmaceuticals Inc 2018-11-26 Glioma; Neuroblastoma; Sarcoma; Sarcoma, Ewing; Osteosarcoma; Histiocytosis, Langerhans-Cell; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Histiocytic Sarcoma; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Multiple Myeloma; Uterine Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Lymphoma; Esophageal adenocarcinoma; Neoplasms, Neuroepithelial; Thyroid Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Xanthogranuloma, Juvenile; Uterine Cervical Neoplasms; Melanoma; Stomach Neoplasms; Solid tumours; Leukemia; Ependymoma; Medulloblastoma; Rhabdomyosarcoma; Liver Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Hepatoblastoma; Rhabdoid Tumor; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Fibrosarcoma; Esophageal Neoplasms; Rectal Neoplasms; Wilms Tumor; Skin Neoplasms; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Central Nervous System Neo Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Merestinib 5OGS5K699E; LY-2801653 Phase 2 Clinical Eli Lilly And Company Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Lymphoma, Mantle-Cell; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
HG-030 HG-030 Phase 1 Clinical Hitgen Inc Solid tumours Details
Lestaurtinib SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 Phase 3 Clinical Kyowa Hakko Kirin Co Ltd Leukemia, Myeloid; Bone Marrow Neoplasms; Leukemia; Polycythemia Vera; Prostatic Neoplasms; Psoriasis; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neuroblastoma; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message